lantus and glp 1 GLP-1 the kidney: from physiology to pharmacology and outcomes in diabetes GLP-1 receptor agonists for individualized

16 Clinicaltrials.gov

(source) A 2017 meta-analysis did not support the suggestion that treatment with GLP-1 agonists or DPP-4 inhibitors increased all-cause mortality in type 2 diabetics

Both Ozempic and Mounjaro belong to the same class of treatments, called GLP-1 agonists, which were initially developed to treat diabetes, but are also approved for obesity.

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme

states where Novi's services have been approved

Advanced CKD (Stage 4-5) and Dialysis Considerations For patients in Stage 4 (GFR 15-29) or Stage 5 (GFR below 15 or on dialysis), the clinical landscape shifts toward a more cautious specialist methodology